Profil
Branden S.
Moriarity holds the position of Chief Scientific Officer at B-MoGen Biotechnologies, Inc., founded in 2015.
Dr. Moriarity holds the position of Chief Innovation Officer at Luminary Therapeutics, Inc., founded in 2019.
Dr. Moriarity is the founder of B-MoGen Biotechnologies, Inc. Dr. Moriarity is the founder of Luminary Therapeutics, Inc. Dr. Moriarity is also the founder of Catamaran Bio, Inc...
Aktive Positionen von Branden S. Moriarity
| Unternehmen | Position | Beginn |
|---|---|---|
B-MoGen Biotechnologies, Inc.
B-MoGen Biotechnologies, Inc. BiotechnologyHealth Technology Provides gene editing solutions for antibody validation, human disease research, gene transfer, and mitochondrial DNA editing | Gründer | 01.01.2015 |
Luminary Therapeutics, Inc.
Luminary Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops non-viral autologous cell therapies | Gründer | 01.01.2019 |
Ehemalige bekannte Positionen von Branden S. Moriarity
| Unternehmen | Position | Ende |
|---|---|---|
Catamaran Bio, Inc.
Catamaran Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company developing allogeneic, off the shelf CAR-NK cell therapies for cancer treatment | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
B-MoGen Biotechnologies, Inc.
B-MoGen Biotechnologies, Inc. BiotechnologyHealth Technology Provides gene editing solutions for antibody validation, human disease research, gene transfer, and mitochondrial DNA editing | Health Technology |
Luminary Therapeutics, Inc.
Luminary Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops non-viral autologous cell therapies | Commercial Services |
Catamaran Bio, Inc.
Catamaran Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company developing allogeneic, off the shelf CAR-NK cell therapies for cancer treatment | Health Technology |
















